0001575872-26-000265
SEC filingDr. Reddy's received Health Canada approval for generic Semaglutide Injection, becoming the first to market in Canada.
Dr. Reddy's Laboratories announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection, making it the first company to obtain marketing authorization for this product in Canada. The approval covers two strengths: 2 mg/pen and 4 mg/pen. This milestone underscores Dr. Reddy's expertise in complex generics and peptide-based therapeutics, supported by in-house API and formulation development. The API is produced entirely in-house, while finished product manufacturing is handled by OneSource Specialty Pharma. With launch preparations underway, Dr. Reddy's is positioned to provide an affordable treatment option for the approximately 3.9 million Canadians living with diagnosed diabetes. The approval also enhances Dr. Reddy's diabetes management portfolio in a key regulated market.